Trans-Scleral Controlled-Release of Drugs for Cataract Surgery by Anselmo G. De Oliveira et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Trans-Scleral Controlled-Release of  
Drugs for Cataract Surgery 
Anselmo G. De Oliveira1, José A. Cardillo2,3, Fernando Paganelli2,3,  
Acácio A. S. Lima-Filho2 and Arnóbio A. Da Silva-Júnior4 
1State of Sao Paulo University-UNESP, School of Pharmaceutical Sciences,  
Department of Pharmaceutics, Araraquara, SP,  
2Federal University of Sao Paulo-UNIFESP,  
Department of Ophthalmology, São Paulo, SP,  
3Eye Hospital of Araraquara, Rua Padre Duarte, Araraquara, SP,  
4Federal University of Rio Grande do Norte-UFRN, Health Sciences Centre, Natal, RN,  
Brazil 
1. Introduction 
In the modern cataract surgery era, postsurgical inflammation is minimal, and a more 
comprehensive medical management strategy to treat such inflammation is still to be 
determined. Historically, corticosteroids have been the drugs of choice for the prevention or 
of postoperative ocular inflammation and are commonly used for several weeks. Surodex, 
an intraocular sustained release pellet of dexametasone has proven to be effective in 
eliminating the necessity for postoperative topical therapy, at the cost of potential 
movement and displacement side effects (Tan et al., 1999; Chang et al., 1999; Tan et al., 
2001). In addition, there is no sufficient literature evidence to support its routine clinical 
acceptance. The sustained anti-inflammatory effects associated with the use of triamcinolone 
in the ophthalmic setting have prompted the authors to consider its therapeutic use for 
controlling post cataract surgery inflammation. A sub–Tenon’s capsule depot corticosteroid 
injection may satisfy all the requirements for an ideal anti-inflammatory strategy and may 
have distinct advantages for reducing complications related to patient noncompliance with 
eye drop administration. 
Our published study comparing a single intraoperative sub-Tenon’s capsule injection of 
triamcinolone with conventional prednisolone eye drops substantiates a novel and more 
comprehensive anti-inflammatory strategy for cataract surgery (Paganelli et al., 2004). 
Consistent with other investigations (West, Behrens & McDonnell, 2005; Negi, Browning & 
Vernon, 2006) our results indicated that one 25-mg sub-Tenon’s capsule triamcinolone 
acetonide injection resulted in a therapeutic response and ocular tolerance comparable to 1% 
prednisolone acetate drops in controlling the signs and symptoms of ocular inflammation 
after cataract surgery. On the first post-operative day, all patients in both groups had 
anterior chamber cell and flare scores that gradually decreased over time. The parallel 
decreases in both groups suggested that triamcinolone is at least as effective as conventional 
prednisolone eye drops in reducing post-operative inflammation. As a result, a sub-Tenon’s 
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capsule injection of depot corticosteroid, an already accepted method for the treatment of 
various inflammatory ocular diseases, could be useful in the surgical arena. It provides a 
new way to eliminate patient self-medicating, avoiding problems with compliance and 
instruction. Furthermore, when this demonstration of the anti-inflammatory effects is 
coupled with its ability to treat cystoids macular edema and diabetic macular edema 
aggravated by cataract, (Yoshikawa et al, 1995; Thach et al., 1997; Walton, Wick & Greewald, 
1999; Cardillo et al., 2005; Kim et al., 2008) a clear role for triamcinolone as a simple and 
more rational management strategy for post-cataract surgical inflammation begins to 
emerge. 
One posterior sub-Tenon’s capsule triamcinolone injection also had ocular tolerance 
equivalent to prednisolone eye drops through 4 weeks of follow-up. There were no 
significant differences between the two treatment groups in the number of adverse events, 
changes in visual acuity (VA), or lack of response. The potential complications of sub-
Tenon’s capsule injection of corticosteroids include inadvertent injection into the choroidal 
or retinal circulation, (McClean, 1975; Ellis, 1978; Morgan et al., 1988) globe perforation, 
(Giles, 1974; Schlaegel & Wilson, 1974; Schechter, 1985) and occlusion of the central retinal 
artery (Ellis, 1978), blepharoptosis, proptosis, orbital fat atrophy, delayed hypersensitivity 
reactions, strabismus, conjunctival hemorrhage, chemosis, and infection also have been 
reported (Ellis, 1974; Nozik, 1976; O’Connors, 1976; Mathias et al., 1978). Although both 
studies are not adequately powered to detect rare complications, these complications were 
not observed. 
An increase in intraocular pressure (IOP) after topical or systemic administration of 
corticosteroids is of particular concern (Herschler, 1976). Patients who receive sub-
Tenon’s capsule injections of corticosteroids may not respond to maximal anti-
glaucomatous therapy and, therefore, may require surgical excision of the depot because 
of a persistently elevated IOP (Akduman et al., 1996). As increased IOP may be a function 
of the interaction between the disease itself and the use of topical or systemic 
corticosteroids - the role of posterior sub-Tenon’s capsule corticosteroids in ocular 
hypertension is not always clear. Therefore these concerns may not apply to patients who 
underwent surgery whose status in responding to corticosteroids is unknown. Following 
a posterior 40-mg triamcinolone sub-Tenon’s capsule injection, an incidence of increased 
IOP that was lower than expected was surprisingly observed (Paganelli et al., 2004). In 
our most recently study, only one eye (triamcinolone group) had an IOP that exceeded 25 
mmHg, and the IOP returned to a normal level with topical antihypertensive drops 
(Paganelli et al., 2009). However, beyond our 28-day follow-up period, delayed onset of 
increased IOP must be considered. The depot formulation was placed forward under sub-
Tenon’s capsule and, if an intractable IOP increase occurred, the remainder of the depot 
could have been easily removed. 
Other authors have also confirmed our theory and similar results have been published 
applying a similar technique targeting operations in cataract and retina surgery (Negi, 
Browning & Vernon, 2006). Although we cannot draw definitive conclusions based on these 
initial findings, the results suggest further investigation is needed. A large phase III 
multicenter trial is being considered to evaluate this potential treatment. Investigation of the 
latest-generation fluoroquinolone formulation combined with non-steroidal anti-
inflammatory drugs is currently underway in our laboratory and will be the next level of 
improvement for this suggested system. 
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This suggested anti-inflammatory approach provides the ophthalmologist with an 
alternative tool to costly controlled drug delivery and eliminates the need for patient self-
medication, which avoids problems with compliance and instruction. Such an approach 
could be especially important in the third world, where topical medications may not be 
available after intraocular surgery. 
2. Anti-infection prophylaxis for cataract surgery 
The achievement of high antibiotic concentrations within infected tissue is important for a 
number of reasons. First of all, in order for the therapy to be effective, the necessary 
bactericidal concentrations to eradicate the pathogen must be achieved and maintained. 
The bactericidal activity of fluoroquinolone is largely concentration-dependent, which 
explains why peak concentration values and the 24-hour area under curve (AUC) are 
important determinants of individual drug activity (potency). Higher drug exposure and 
total dosages, as indicated by higher AUCs, may be associated with more effective 
eradication of the infecting organism (Paccola, Jorge & Barbosa, 2007). Second, the 
emergence of bacterial resistance to fluoroquinolone also appears to be concentration-
dependent (Bui, Dang & Hwang, 1995; MacDonald, 2006). At fluoroquinolone 
concentrations above the minimum inhibitory concentration (MIC), the frequency of 
bacterial mutation increases exponentially as the concentration decreases. This means that 
the employment of fluoroquinolone that can result in tissue concentrations only modestly 
above the MIC could result in the development of antibiotic resistance to that specific 
fluoroquinolone (Bui, Dang & Hwang, 1995). Thus, the ability of a drug to produce high 
drug concentrations within infected tissues may facilitate enhanced antibacterial activity 
with a reduced likelihood of emergence of resistance. For a future and revolutionizing 
therapy, this required target could only be achieved by the development of an eye-specific 
antimicrobial agent or by an appropriate drug delivery approach engineered to enhance 
drug penetration (Velpandian, 2009). 
3. Conventional antimicrobial strategy and its limitations 
The route for local ophthalmic drug delivery remains the topical application of solutions 
at the surface of the eye as drops. Drug delivery to intraocular tissues by this approach, 
however, is limited by: (A) the significant barrier to solute flux provided by the corneal 
epithelium; and (B) the precorneal drug loss that occurs by way of the tear fluid turnover. 
Although a relatively small fraction of the dose applied topically reaches the intraocular 
tissues, the topical formulations can deliver therapeutic concentrations in tissues of the 
anterior segment, mainly because the administration of a high dose of the drug is 
necessary. It has been estimated that typically less than 5% of a topically applied drug 
actually permeates the cornea and eventually reaches intraocular tissues. The major 
portion of the instilled dose is absorbed systemically by way of the conjunctiva, through 
the highly vascular conjunctival stroma and through the lid margin vessels. Additionally, 
systemic absorption also occurs when the solution enters the nasolacrimal duct and is 
absorbed by the nasal and nasopharyngeal mucosa (Lang, 1996; Geroski & Edelhauser, 
2001). 
Conventional ocular pharmacokinetic views have downplayed the possibility of any 
highly effective transfer of a drug from an eye drop to the aqueous and vitreous humor. 
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Widely accepted for conjunctival and corneal infection, new antibiotic drops are often 
exploited for prophylactic use without rationalizing the penetration characteristics in the 
drug development stage. Interesting, in the currently clinical scenario, in contradiction 
with the physiological processes involved in guarding the eye against xenobiotics, the 
newer fluoroquinolone have been marketed partly on the basis of their excellent ocular 
penetration after topical administration - but at the cost of extremely artificial supportive 
methods used in their development (Kim et al., 2005; Sollomon, Donnenfeld & Perry, 
2005). A careful literature and methods review of the relevant studies will point to an 
unacceptable high antibiotic loading dose and single point measurement (usually at a 
short- and higher peak concentration-time point) which is used to demonstrate the 
potential of the newer-generation fluoroquinolones to overcome these barriers to drug 
delivery. Tested in a practical clinical setting, where a single drop is instilled ever four to 
six hours and poor patient compliance to the treatment is a common issue, even later 
generation antibiotics may face obstacles in reaching high and even more importantly 
sustained therapeutic levels. In support of our theory against topical antibiotic delivery in 
cataract surgery, our laboratory has elaborated a more simplistic and realistic 
investigation method to experimentally address the role of topical prophylaxis in the 
surgical scenario. 
An aqueous humor bioactivity comparison of several fluorquiniolones following a single 
topical drop delivery was carried out in our laboratory with the single purpose of 
evaluating quantitatively over time the bioactivity of ciprofloxacin 0.3%, levofloxacin 1.5%. 
gatifloxacin 0.3% and moxifloxacin 0.5% in the aqueous humor of rabbit eyes. For 
supportive methods, a total of 64 New Zealand rabbit eyes were topically treated with a 
commercially available formulation of ciprofloxacin 0.3%, levofloxacin 1.5%, gatifloxacin 
0.3% and moxifloxacin 0.5% eye drops. Following an initial loading dose consistent with a 
single antibiotic drop the aqueous humor was sampled at 30 minutes, 1, 2 and 4 hours post-
treatment. Biological activity was indirectly determined from the size of the zone of 
inhibition (ZOI) of filter paper disc soaked in 25l of aqueous humor drawn from treated 
eyes and placed on an agar plate surface-cultured with Staphylococcus Epidermidis. To our 
amazement, but theoretically expected, although not significant, 0.5% moxifloxacin eye 
drops showed an initial (30 minutes and 1 hour post-treatment) trend towards superior 
aqueous bioactivity compared to all other tested formulations (Figure 1). At and following 
the second hour, the aqueous humor drawn from all treated eyes failed to demonstrate any 
bacterial inhibitory potential for the four tested formulations, since no zone of inhibition 
could be observed. The main conclusion of this method of antibiotic-bioactivity exploration 
is that sole reliance on the minimum inhibitory concentration and artificial 
pharmacokinetics studies as guides to antibacterial efficacy may be misleading and even 
newer-generation fluorquiniolones failed to demonstrate a significant aqueous bioactivity 
using a dosing regimen that simulated prophylactic use after cataract surgery (Paganelli et 
al., 2010). 
Despite surrogate studies showing that topical antibiotics decrease bacteria on the ocular 
surface and anterior chamber, and that some topical antibiotics can penetrate the cornea and 
the anterior chamber (Callegan et al., 2003; Price, Quillin & Price Jr, 2005; Sollomon, 
Donnenfeld & Perry, 2005), there has not been a prospective randomized study showing 
that topical antibiotics prevent endophthalmitis. Bioavailability has been touted in the 
literature, but its relationship to endophthalmitis in the human is unknown. In one rabbit 
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study, several drops of moxifloxacin administered preoperatively prevented 
endophthalmitis from developing (Kowalski et al., 2004). This was the first study to suggest 
that topical antibiotics alone can prevent endophthalmitis. Once an organism reaches the 
vitreous, however, topical application of antibiotics is probably not efficacious (Costello et 
al., 2006). Furthermore, in vitro susceptibility data and animal studies cannot be translated 
uniformly into a solid and reliable assessment of in vivo efficacy because of additional 
factors such as anatomic location and pharmacodynamics. 
 
  
(a) (b) 
 
  
(c) (d) 
Fig. 1. Aqueous humor bioactivity following the delivery of a single topical drop of 
moxifloxacin 0.5% evaluated quantitatively over time: (a) 30 minutes, (b) 1 hour, (c) 2 hours 
and (d) 4 hours post drop-instillation (Paganelli et al., 2010). 
4. Technological strategy of micro and nanoparticles for ocular trans-scleral 
drug delivery 
Research and development in the area of pharmaceutical biotechnology has introduced an 
increasing number of therapeutic possibilities for medical treatment of many diseases, 
especially ocular diseases. The field of drug-controlled release represents a frontier area in 
medical science, involves a broad multidisciplinary approach, and has contributed 
decisively to improving human health. The systems offer clear advantages compared with 
conventional drug dosage forms, such as increasing the drug efficiency, reduced toxicity, 
increased patient compliance, improved safety and patient comfort (Zeimer & Goldberg 
2001). 
Sustained drug delivery devices offer an excellent alternative to solve many problems 
associated with patient use of postoperative drops in cataract surgery. These devices are 
made either from biostable (non-biodegradable, non-erodible), or from biodegradable 
(erodible) polymers. The erodible devices have an inherent advantage over the non-erodible 
systems in that as they degrade they gradually disappear from the site of implantation. The 
particles consist of drugs entrapped within a polymer, and are frequently classified by size 
into microparticles (> 1 m) and nanoparticles (< 1 m). According to physical structure, the 
microparticles are classified as microspheres and microcapsules. Microcapsules have a drug 
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core surrounded by a polymeric film, while in the microspheres the drug is dispersed 
through the polymeric matrix. The aim in the development of microspheres and 
microcapsules has been to develop long-acting injectable drug depot formulations with 
specific drug targeting and delivery optimization (Herrero-Vanrell & Refojo 2001). These 
systems have been under evaluation for ophthalmic drug delivery purposes for the past 20 
years. Among the biodegradable polymers that have been investigated to make 
microparticles for drug delivery are gelatin, albumin, polyorthoesters, polyanhydrides, and 
polyesters, particularly polymers of polylactide acid (PLA), polyglicolic acid (PGA), and 
poly (lactide-co-glycolide) acid (PLGA). These polyesters have been most frequently used to 
make microspheres for subconjunctival and intravitreous drug delivery. Among the 
polymeric particles potentially useful for ocular drug delivery, the microspheres have been 
most commonly used, mainly due to the delivery possibility through conventional small-
gauge syringes (Herrero-Vanrell & Refojo, 2001). 
In our studies, the spray drying technique was used to produce biocompatible microspheres 
that were uniform in shape and size, sterilized by gamma radiation, and suitable for ocular 
administration. The great advantage of this methodology is that it produces dried 
microspheres of small size and free of solvent residues and other compounds needed in the 
emulsification methods. The mean particle sizes and encapsulation efficiencies were 1.03 (± 
0.30) m and 97.86% (±0.96%), respectively. These systems have proved to be suitable for 
subconjunctival and intraocular injection displaying pharmacokinetic profiles with high and 
prolonged drug concentration in aqueous and vitreous humors (Silva-Jr et al., 2008; Silva-Jr 
et al., 2009). Figure 2 shows the the images of the scanning electron microscopy of 
ciprofloxacin-loaded PLGA microspheres utilized in most of our studies. 
Subconjunctival ocular drug delivery represents another attempt to elevate intraocular drug 
concentrations and minimize the frequency of dosing (Hosoya, Lee & Kim, 2005). 
 
 
 
 
Fig. 2. Scanning electron microscopy images of ciprofloxacin-loaded PLGA microspheres 
with drug/polymer proportions of (A) 1:1; (B) 1:2; (C) 1:3 and (D) 1:5 (w/w). 
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Compared with direct intraocular injection, this approach is less risky to the patient and 
less invasive. Since sclera is much more permeable than conjunctiva, the formidable 
permeability barrier consisted of both cornea and conjunctiva can be avoided altogether in 
such approaches (Olsen et al., 1995; Hosoya, Lee & Kim, 2005). The advantage of 
subconjunctival implants as opposed to conjunctival injection of solution is the 
achievement of higher drug concentrations and sustained release of the drug in both 
aqueous and vitreous humor and even retinal areas (Gilbert et al., 2003). Dl-polylactide 
(PLA) nano- and microparticles containing budesonide (which inhibits the expression of 
vascular endothelial growth factor (VEGF) for the treatment of angiogenesis in the retina) 
are reported to afford sustained release of budesonide in vitro. Subconjunctival injection 
of PLA microparticles (3.6 m) led to a much higher budesonide concentration in retina 
and vitreous humor over 14 days, compared with the solution form of dosing and PLA 
nanoparticle (345 nm) administration (Kompella, Bandi & Yalasomayajula, 2003). It was 
previously published that the collagen matrix and fibrin sealant provided a better 
controlled release of cisplatin and carboplatin, respectively, than the conventional drug 
solution, attaining higher drug concentrations after subconjunctival administration using 
rabbits in several ocular tissues including retina (Simpson et al., 2002; Gilbert et al., 2003). 
Trans-scleral delivery is a minimally invasive method that achieves targeted delivery of 
higher therapeutic levels of anti-infection and anti-inflammatory drugs to the anterior and 
posterior segments of the eye. This drug delivery modality exhibits linear kinetics of 
absorption and elimination, with potential to deliver a constant drug concentration. By 
bridging the potential of later generation antibiotics, trans-scleral delivery of 
biodegradable microparticles sits at the crossroads of patient comfort, treatment 
compliance, and enhanced safety. 
5. Subconjunctival delivery of antibiotic in controlled-release microspheres 
Lack of commercial viability in conjunction with an absence of clarity or consensus about 
the mechanisms of ocular drug penetration and accurate drug delivery has translated 
into attenuated enthusiasm among pharmaceutical companies and researchers. This 
hinders the exploration of novel therapeutic approaches for the eye with appropriate 
newer molecules and better engineered drug delivery technologies. To the best of our 
knowledge our recently published investigations open up a new era offering the 
potential of no need for postoperative drops in cataract surgery (Paganelli et al., 2004; 
Paganelli et al., 2009; Cardillo et al., 2010). These studies gave new information and 
substantiated a novel and optimized antibiotic prophylaxis strategy using slow delivery 
technology. Superior vitreous penetration and immediately higher concentrations of 
antibiotic in the aqueous humor, when compared with the common practice of dosing 
eye drops 6-times-daily, both support and add rationale to the use of a slow-release 
trans-scleral drug delivery system in preventing endophthalmitis after cataract surgery. 
In addition, when this pharmacologic achievement is coupled with its ability to free the 
patient from the difficulties posed by topical administration, a clear role for this system 
as a simple and more comprehensive weapon for fighting postoperative infections begins 
to emerge. 
By exploring superior sclera permeability and to avoid the rate-limiting barriers of the 
cornea and conjunctiva, subconjunctival routes may offer a promising alternative for 
enhanced drug delivery and tissue-targeting compared with topical routes (Clements & 
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Tailor, 1987; Behrens-Baumann & Martell, 1988; Barza, 1989; Starr & Lally, 1995; Prausnitz & 
Noonan, 1998). Confirming our premise, the controlled-release microsphere delivered 
therapeutic concentrations of antibiotic greater than the minimum inhibitory concentration 
for most common ocular pathogens up to 10 days after injection. The dosing regimen tested 
in this experimental investigation fits into a realistic clinical scenario and may provide a 
surrogate to assess achievable postoperative concentrations. Similar to previous studies 
(Gilbert et al., 2003; Kompella & Bandi, 2003; Kosoya, Lee & Kim, 2005) the parallel and 
higher aqueous and vitreous levels of ciprofloxacin-loaded microspheres, as opposed to the 
same concentration of ciprofloxacin in its free form after a single subconjunctival injection 
and to topical ciprofloxacin delivery, are considered a highly desirable pharmacological 
achievement. Furthermore, given the inherent advantages of intraoperative sustained-
release antibiotics, particularly patient compliance and convenience, the studied system may 
achieve a breakthrough in the development of more successful treatment modalities, 
suggesting a possible new way to progress anti-infection prophylaxis in parallel with 
antibiotic drug development. 
In an experimental rabbit model of endophthalmitis prophylaxis, we have demonstrated 
that prophylaxis with a biodegradable controlled-release system trans-scleral delivered 
through a single subconjunctival injection can reach sustained therapeutic levels in the 
anterior chamber that predictably reduced bacterial recovery and signs of clinical 
endophthalmitis (comparable to conventional topical drops). Extrapolating these findings to 
clinical settings, where typically patients are noncompliant with treatment, we could 
postulate and expect a superior performance for microspheres system over conventional 
postoperative drops. The frequency of application is important for attaining adequate 
antibacterial concentrations, and poor compliance also prevents the drops from reaching 
efficacious levels. Compliance with topical therapy was studied using an electronic device in 
ambulatory patients who underwent cataract surgery; all patients were noncompliant 
regarding total dose, time intervals, and premature discontinuation of therapy (Hermann, 
Ustundag & Diestelhorst, 2005). 
Since adverse events are an important concern with any new dosage form, it is also 
important to ensure that the system chosen for prophylaxis following cataract surgery is safe 
and well-tolerated, eliminating any potential toxic effects. The biocompatibility of periocular 
microspheres of biodegradable polymers has been extensively investigated. In vivo there 
were no drug or procedure-related adverse events and no inflammatory cells or fibrous 
tissue response at the site of injection was observed. Clinically, in addition to its minimally 
invasive and pharmaceutically acceptable nature, no drug or procedure-related adverse 
events occurred (Paganelli et al., 2009; Cardillo et al., 2010). 
Pharmacokinetic profiles of aqueous and vitreous humor in rabbit eyes using 0.2 mg/0.1mL 
of ciprofloxacin microspheres or 2 mg/0.1mL of free ciprofloxacin were compared to a 
single drop of 0.3% ciprofloxacin six times a day. In 45 rabbits, Staphylococcus aureus was 
injected into the anterior chamber and 15 were randomly chosen to receive 1 drop of 0.3% 
ciprofloxacin every 4 hours during 24 hours, 15 received drops of basic salt solution (BSS), 
and 15 received ciprofloxacin microspheres. After 24 hours endophthalmitis score were 
recorded, aqueous and vitreous humors were cultured and histology was performed. The 
subconjunctival administration of non-encapsulate ciprofloxacin exhibited a rapid 
absorption and permeation between aqueous and vitreous humors, with sharp decay within 
6 hours of application (Fig. 3). 
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Fig. 3. Comparative pharmacokinetic profiles between the aqueous and vitreous humors 
after subconjunctival injection of the non-encapsulated ciprofloxacin (2mg/0.1ml). Key: () 
aqueous humor, () vitreous humor. 
Compared to ciprofloxacin solution injection and ciprofloxacin eye drops, drug levels in the 
microspheres group showed an immediate and sustained trend towards increased aqueous 
and vitreous penetration (Fig. 4). A distinct pharmacokinetic trend was observed when the 
microsphere group was compared with the topical administration group. In the 8 hour-
period studied for this group in the design, an immediate higher intraocular antibiotic level 
was found in the microsphere group, except for the fifth hour that demonstrated 
comparable measurements. At this time point, one hour prior to sampling, an extra drop of 
ciprofloxacin was instilled, following the pre-established schedule of one loading drop 
every 4 hours (Fig. 4). 
 
Fig. 4. Comparative pharmacokinetic of ciprofloxacin in the aqueous humor after the single 
subconjunctival injection of CP (ciprofloxacin)-loaded PLGA microparticles (2mg/0.1ml) () 
and topical CP eye drops 0.3% (). 
Comparing the aqueous concentration following a single subconjunctival injection of the 
ciprofloxacin-loaded microspheres to the regular ciprofloxacin formulation, a statistically 
significant difference in favor of the microspheres group was noticed immediately following 
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drug administration and sustained throughout the entire study period. The system allowed 
sustained aqueous humor concentration of ciprofloxacin in the therapeutic range for most 
common ocular pathogens (2μg/mL) for up to 8 days (Fig. 5). 
 
Fig. 5. Comparative pharmacokinetic of ciprofloxacin in the aqueous and vitreous humors 
subconjunctival administration of 2mg/0.1ml of CP-loaded microparticles. Key: () 
aqueous humor, () vitreous humor. 
In contrast to the ciprofloxacin microspheres and solution groups, no measurable levels of 
ciprofloxacin could be detected in the vitreous cavity following topical administration. 
Assessing the vitreous concentration, a statistical significant difference in favor of the 
microspheres group was immediately noticed following drug administration and sustained 
throughout the entire study period. 
6. Conclusions 
Our scientific observations suggest that a trans-scleral antibiotic delivery system is both 
effective and may help to eliminate patient noncompliance. By freeing the patient from the 
hassles and expenses of topical therapy post cataract surgery, a new anti-inflammatory and 
anti-infection paradigm in modern cataract surgery has been introduced, meriting further 
consideration. In parallel to antibiotic development, exploiting the routes for trans-scleral 
delivery or circumventing the cornea-conjunctival barriers will be the key to an ultimate 
anti-infection strategy in the modern cataract surgery era. While the challenges are 
formidable, the experimentally and clinically tested systems hold promise for new 
paradigms in dosing anterior segment drugs. However, no study will provide the final 
answer regarding optimum antibiotic prophylaxis in this continually developing field. 
Advances in antimicrobial therapy and modes of delivery make this a dynamic area and 
highlight the need for continued investigation and periodic guideline reviews to keep pace 
with new developments to optimize patient care. 
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